Monday morning kicks off one of the largest biotech events of the year: the JP Morgan Healthcare Conference. This conference is a four day event of the “who’s who” in the world of biotech. Here, companies large and small will present their 2019 milestones achieved, and pitch their aspirations for 2020 and beyond to investors and larger pharma companies. Often, companies will pre-announce sales for the year/quarter ended December 31st, 2019. This also provides a great venue to announce and tout new collaborations, or in the case of LOXO Oncology and Eli Lilly, announce a new blockbuster merger. So what are we watching this year? Well here our team briefly outlines two companies that we are each intrigued by and why.
Chris (CPO): This year at JPM20 I am closely watching TG Therapeutics (TGTX) and Nantkwest (NK). TG Therapeutics has been covered by us previously, and recently secured additional funding, which helps their balance sheet. They have a packed 2020 planned with several key pivotal trial readouts and a planned NDA filing. This year has the making for a pivotal time in TG Therapeutic’s history. On a smaller front, Nantkwest seeks to harness the innate immune system by uses off-the shelf Natural Killer cells. In late 2019, they announced positive data at the San Antonio Breast Cancer Symposium for patients with late line triple-negative breast cancer. I am very curious to see how they outline their priorities for 2020 and what expectations they set for the year.
For those interested, the full conference agenda is placed below:
This is not a recommendation to buy/sell securities.
I/we long TGTX.